검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-CD123 CAR NK cells (Anti-CD123 CAR NK cells) Chongqing Precision Biotech Co., L…·AML (Acute Myeloid Leukemia) 2 trials |
|---|---|
Overview Program | Anti-CD123 CAR NK cells |
Overview Company | Chongqing Precision Biotech Co., Ltd |
Overview Modality | CGT |
Overview Target | AML (Acute Myeloid Leukemia) |
Overview Indication | AML (Acute Myeloid Leukemia); BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | target the IL-3 receptor |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.. The treatment of B cell malignancies has dramatically changed with the introduction of immunotherapy, especially chimeric antigen receptor T (CAR-T) cell therapy. However, only limited efficacy is observed in acute myeloid leukaemia (AML). In the study, We detected CD123 and CLL-1 expression on leukaemia cells from Re… |
Clinical Data Tier / Score | A · 10 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-CD123 CAR NK cells (Anti-CD123 CAR NK cells) Chongqing Precision Biotech Co., L…·AML (Acute Myeloid Leukemia) 2 trials |
|---|---|
Overview Program | Anti-CD123 CAR NK cells |
Overview Company | Chongqing Precision Biotech Co., Ltd |
Overview Modality | CGT |
Overview Target | AML (Acute Myeloid Leukemia) |
Overview Indication | AML (Acute Myeloid Leukemia); BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | target the IL-3 receptor |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.. The treatment of B cell malignancies has dramatically changed with the introduction of immunotherapy, especially chimeric antigen receptor T (CAR-T) cell therapy. However, only limited efficacy is observed in acute myeloid leukaemia (AML). In the study, We detected CD123 and CLL-1 expression on leukaemia cells from Re… |
Clinical Data Tier / Score | A · 10 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교